A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
- PMID: 21850690
- DOI: 10.1002/lt.22417
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Abstract
This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA-positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade ≥ 3 and/or a fibrosis stage ≥ 2) in years 1 (48.2%, 50.4%, and 43.0%, respectively) and 2 (69.5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS.
Copyright © 2011 American Association for the Study of Liver Diseases.
Similar articles
-
Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.Transplantation. 2012 Sep 15;94(5):492-8. doi: 10.1097/TP.0b013e31825c1d6c. Transplantation. 2012. PMID: 22858806 Clinical Trial.
-
Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.Liver Transpl. 2007 Nov;13(11):1521-31. doi: 10.1002/lt.21182. Liver Transpl. 2007. PMID: 17969201 Clinical Trial.
-
Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.Transplantation. 2008 Dec 27;86(12):1689-94. doi: 10.1097/TP.0b013e31818fff64. Transplantation. 2008. PMID: 19104406 Clinical Trial.
-
Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.World J Gastroenterol. 2014 Sep 14;20(34):12330-40. doi: 10.3748/wjg.v20.i34.12330. World J Gastroenterol. 2014. PMID: 25232269 Free PMC article. Review.
-
Immunosuppression in HCV-positive liver-transplant recipients.Curr Opin Organ Transplant. 2012 Dec;17(6):648-54. doi: 10.1097/MOT.0b013e32835a2b5a. Curr Opin Organ Transplant. 2012. PMID: 23128793 Review.
Cited by
-
Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients.Dis Markers. 2014;2014:202548. doi: 10.1155/2014/202548. Epub 2014 Feb 18. Dis Markers. 2014. PMID: 24695489 Free PMC article.
-
Challenges of recurrent hepatitis C in the liver transplant patient.World J Gastroenterol. 2014 Apr 7;20(13):3391-400. doi: 10.3748/wjg.v20.i13.3391. World J Gastroenterol. 2014. PMID: 24707122 Free PMC article. Review.
-
Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review.World J Gastroenterol. 2014 Aug 21;20(31):10703-14. doi: 10.3748/wjg.v20.i31.10703. World J Gastroenterol. 2014. PMID: 25152574 Free PMC article. Review.
-
Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.Clin Gastroenterol Hepatol. 2013 Dec;11(12):1655-60.e1. doi: 10.1016/j.cgh.2013.07.014. Epub 2013 Jul 23. Clin Gastroenterol Hepatol. 2013. PMID: 23891915 Free PMC article.
-
Early coupled up-regulation of interleukin-12 receptor beta-1 in CD8+ central memory and effector T cells for better clinical outcomes in liver transplant recipients.Clin Exp Immunol. 2015 Aug;181(2):373-84. doi: 10.1111/cei.12588. Clin Exp Immunol. 2015. PMID: 25603847 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical